Bionano GenomicsBNGO
About: Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.
Employees: 100
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
460% more call options, than puts
Call options by funds: $56K | Put options by funds: $10K
43% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 7
40% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 10
2% more funds holding
Funds holding: 51 [Q3] → 52 (+1) [Q4]
0.39% less ownership
Funds ownership: 6.35% [Q3] → 5.96% (-0.39%) [Q4]
29% less capital invested
Capital invested by funds: $2.47M [Q3] → $1.75M (-$720K) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co. Yi Chen 34% 1-year accuracy 57 / 170 met price target | 133%upside $10 | Buy Initiated | 9 Apr 2025 |
Scotiabank Sung Ji Nam 8% 1-year accuracy 2 / 24 met price target | 7%downside $4 | Sector Perform Maintained | 2 Apr 2025 |
Financial journalist opinion
Based on 4 articles about BNGO published over the past 30 days









